A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
Clinical trial NCT05795153 · COMPLETED
Trial details
- NCT number
- NCT05795153
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-05
- Primary completion
- 2024-04-25
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.